Helen Torley Halozyme Therapeutics, Inc. (HALO) insider trading activity

Helen Torley is PRESIDENT AND CEO of HALOZYME THERAPEUTICS, INC.. Currently has a direct ownership of 733,719 shares of HALO, which is worth approximately $43.4 Million. The most recent transaction as insider was on Feb 23, 2025, when has been sold 12,081 shares (Common Stock) at a price of $57.75 per share, resulting in proceeds of $697,677. This information was disclosed in a Form 4 filing with the Securities and Exchange Commission (SEC).

Shares Held (Direct Ownership) 734K

10.05% 3M change

8.42% 12M change

Total Value Held $43.4 Million

Helen Torley Transaction History

Date	Transaction	Value	Shares Traded	Shares Held
Feb 23 2025	SELL Payment of exercise price or tax liability	$697,677 $57.75 p/Share	12,081 Reduced 1.62%	733,719 Common Stock
Feb 23 2025	BUY Exercise of conversion of derivative security	-	22,436 Added 2.92%	745,800 Common Stock
Feb 16 2025	SELL Payment of exercise price or tax liability	$3,443,073 $58.29 p/Share	59,068 Reduced 7.55%	723,364 Common Stock
Feb 16 2025	BUY Exercise of conversion of derivative security	-	109,694 Added 13.03%	732,451 Common Stock
Feb 15 2025	SELL Payment of exercise price or tax liability	$413,742 $58.29 p/Share	7,098 Reduced 1.04%	672,738 Common Stock
Feb 15 2025	BUY Exercise of conversion of derivative security	-	13,092 Added 1.89%	679,836 Common Stock
Nov 29 2024	SELL Bona fide gift	-	10,000 Reduced 1.48%	666,744 Common Stock
Oct 09 2024	SELL Open market or private sale	$530,200 $53.02 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Oct 09 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Oct 08 2024	SELL Open market or private sale	$542,500 $54.25 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Oct 08 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 26 2024	SELL Open market or private sale	$561,000 $56.1 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 26 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 25 2024	SELL Open market or private sale	$563,400 $56.34 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 25 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 24 2024	SELL Open market or private sale	$582,100 $58.21 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 24 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 12 2024	SELL Open market or private sale	$592,000 $59.2 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 12 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 11 2024	SELL Open market or private sale	$590,900 $59.09 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 11 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Sep 10 2024	SELL Open market or private sale	$590,900 $59.09 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Sep 10 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock
Aug 15 2024	SELL Open market or private sale	$579,500 $57.95 p/Share	10,000 Reduced 1.46%	676,744 Common Stock
Aug 15 2024	BUY Exercise of conversion of derivative security	$138,700 $13.87 p/Share	10,000 Added 1.44%	686,744 Common Stock

Also insider at

DGX

QUEST DIAGNOSTICS INC Healthcare

Director

Helen Torley

PRESIDENT AND CEO

Secaucus, NJ

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells HALO shares.

Notify only if

Value

Insider Trading

Get notified when an Halozyme Therapeutics, Inc. insider buys or sells HALO shares.

Notify only if

Operation

Value

Type

News

Receive news related to HALOZYME THERAPEUTICS, INC.

Track Activities on HALO

Account